AT 2604
Alternative Names: AT 04 - Axcynsis Therapeutics; AT-2604Latest Information Update: 11 Jul 2024
At a glance
- Originator Axcynsis Therapeutics
- Class Antineoplastics; Auristatins; Drug conjugates; Immunoconjugates; Immunotoxins; Monoclonal antibodies
- Mechanism of Action Apoptosis stimulants; Mitosis inhibitors; Tubulin inhibitors; Tubulin polymerisation inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Solid tumours
Most Recent Events
- 17 Jun 2024 Axcynsis Therapeutics plans a phase I trial for Solid tumours (Parenteral) in 2025 (Axcynsis Therapeutics pipeline, June 2024)
- 05 Apr 2024 Preclinical trials in Solid tumours in Singapore (Parenteral), prior to April 2024
- 05 Apr 2024 Adverse events and pharmacodynamics data from preclinical trials in Solid tumours presented at the 115th Annual Meeting of the American Association for Cancer Research (AACR-2024)